StageAcquired | Acquired
ProteinSimple, formerly Cell Biosciences, develops and commercializes proprietary systems and consumables for protein analysis that ultimately help reveal new insights into the true nature of proteins. ProteinSimple tools have revolutionized the analysis of proteins and provide a level of reliability, ease of use and performance that improves overall productivity and consistency in lab results.
Missing: ProteinSimple's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: ProteinSimple's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
ProteinSimple has filed 35 patents.
The 3 most popular patent topics include:
- Molecular biology
Latest ProteinSimple News
Jan 24, 2023
Major Players Thermo Fisher Scientific, Inc., GE Healthcare, Hoffmann-La Roche Ltd., Danaher Corporation (Lumigen, Inc.), EMD Millipore Corporation, Bio-Rad Laboratories, Inc., PerkinElmer Inc., LI-COR, Inc., Bio-Techne Corporation (ProteinSimple Inc.), and Advansta, Inc. among other. Segmentation Analysis The gel electrophoresis segment is expected to be the fastest-growing segment in 2022. The product segment is blotting systems, consumables, gel electrophoresis, and imagers. The gel electrophoresis segment is expected to witness the highest growth rate during the forecast period. By utilising an enzyme's or a primary antibody's capacity to bind to a specific antigen, electrophoresis blotting is a highly effective method for detecting a specific protein in a sample. It therefore has strict requirements for a variety of applications. The demand for consumables in blotting systems for research and diagnosis is rising at the fastest rate due to the rising occurrence of contagious illnesses. The western segment is expected to be the fastest-growing segment in 2022. The type segment is northern, western, eastern, and southern. The western segment is expected to witness the highest growth rate during the forecast period. Proteins are separated and identified using the blotting method known as Western blotting, commonly referred to as immunoblotting. Preparing the tissue, electrophoresis on a gel, protein transfer to the membrane, blocking to prevent membrane and antibody interactions, membrane incubation, and antibody-based protein detection are all steps in the western blot procedure. The diagnostics segment is expected to be the fastest-growing segment in 2022. The application segment is agriculture, research, food & beverages, diagnostics, and others. The diagnostics segment is expected to witness the highest growth rate during the forecast period. Scientific research and medical diagnostics are now lucrative in the global blotting systems market, and it is anticipated that they will continue to maintain those positions in the coming years. Due to a growth in research and development efforts and advancements in the medical diagnostics business, these markets have grown to be incredibly lucrative for significant players. Regional Analysis The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the blotting systems include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North America region witnessed a major share. The United States has North America's biggest market. In the approaching years, it is anticipated that sales of blotting systems will be driven by the rapidly developed biotechnology and medical diagnostics sectors. According to a study done by the US Department of Agriculture, farmers' adoption of agricultural biotechnology is changing how this industry is commercialized (USDA). According to reports, the biotechnology sector is fairly developed in the US. The USDA claims that agricultural biotechnology has the potential to enhance US food production and associated R&D initiatives. This is a hidden sign that there is a rise in the demand for blotting systems in the US. Country Analysis Germany Germany's blotting systems market size was valued at USD 0.62 billion in 2022 and is expected to reach USD 0.72 billion by 2030, at a CAGR of 2% from 2023 to 2030. Germany is an important market for people in this industry as it is the centre of the largest blotting systems market in Europe. Due to its rapidly expanding pharmaceutical, medical research, and diagnostics industries, Germany is a target for multinational corporations. Germany's research sector is anticipated to be significantly improved by the EU-funded CANCERSCREEN project, which has assembled a comprehensive global data collection of over 800 businesses in this field. China China’s blotting systems market size was valued at USD 1.36 billion in 2022 and is expected to reach USD 1.86 billion by 2030, at a CAGR of 4% from 2023 to 2030. The medical equipment and diagnostics sector is one of China's fastest-growing businesses, with double-digit growth sustained for more than 10 years, according to the "Healthcare Resource Guide" research, which was issued by the Export Government of China on October 30th, 2019. India India's blotting systems market size was valued at USD 1.02 billion in 2022 and is expected to reach USD 1.29 billion by 2030, at a CAGR of 3% from 2023 to 2030. The market for medical devices and diagnostics is currently worth more than US$ 10 billion, and by 2024, it is expected to increase to US$ 65 billion, according to Invest India, the National Investment Promotion & Facilitation Agency of India. The market for medical equipment, which includes diagnostic tools, is expected to increase at a rate of 28% per year and reach US$ 50 billion by 2025, according to the report. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of the blotting systems market is mainly driven by the rise in applications. Buy Now Full Report @ https://greyviews.com/checkout/442/single_user_license Contact Us
ProteinSimple Frequently Asked Questions (FAQ)
When was ProteinSimple founded?
ProteinSimple was founded in 2001.
Where is ProteinSimple's headquarters?
ProteinSimple's headquarters is located at 3040 Oakmead Village Drive, Santa Clara.
What is ProteinSimple's latest funding round?
ProteinSimple's latest funding round is Acquired.
How much did ProteinSimple raise?
ProteinSimple raised a total of $96.85M.
Who are the investors of ProteinSimple?
Investors of ProteinSimple include Bio-Techne, The Vertical Group, Domain Associates, Novo Holdings, Wellcome Trust and 9 more.
Who are ProteinSimple's competitors?
Competitors of ProteinSimple include ZyGEM, Evogen, NanoString Technologies, eSionic, GenTel BioSciences and 11 more.
Compare ProteinSimple to Competitors
The firm aims to provide powerful tools based on microelectronic technology to scientists involved in basic molecular biology research. Investigating the biological actions of molecules "in vitro" on cultured cells is a fundamental step for drug development and for basic life sciences. Routine techniques for intracellular delivery are high-cost and time-consuming procedures involving the use of a large amount of the candidate molecule and a stochastic interpretation of the results. Thanks to an combination of cell and molecular biology with semiconductor technology the company developed a new technique overcoming these limitations.
Ocimum Biosolutions is a life sciences RnD enabling company with three focus areas, BioIT (LIMS / Bioinformatics), BioMolecules, and BioResearch. Ocimum aims to deliver end to end genomic products and services out of three strategic locations worldwide, Indianapolis (United States), IJsselstien (The Netherlands), Hyderabad (India).
Harvard Bioscience acquires and distributes laboratory equipment and products for companies and institutions in the life sciences field.
Biocom works to drive public policy, build a network of industry leaders, create access to capital, introduce STEM education programs, and create value-driven purchasing programs.
Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Innoprot tGFP-BACE1 HEK293 Cell Line CB2 Internalization Assay Cell Line hGR Nuclear Translocation Assay Cell Line Human Cardiac Myocytes Assay Development Neurotoxicity Assay induced by beta amyloid NEWS Innoprot has been awarded on the Bizkaia Ekinez Prizes 05/06/2009 Innoprot has been awarded on the Bizkaia Ekinez Prizes with the "Gaztedi Prize"
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.